Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés , David W. Cescon , Hope S. Rugo , Javier Cortés , David W. Cescon , Hope S. Rugo , Zbigniew Nowecki , Seock‐Ah Im , Mastura Md Yusof , Carlos Gallardo , Oleg Lipatov , Carlos H. Barrios , Holgado Esther , Hiroji Iwata , Norikazu Masuda , Marco Torregroza Otero , Erhan Gökmen , Sherene Loi , Zifang Guo , Jing Zhao , Gursel Aktan , Vassiliki Karantza , Peter Schmid , F. Vidal Luis , Gomez Abuin Gonzalo , Diego Kaen , Kowalwszyn Ruben , Molina Matias , Varela Mirta , Sally Baron-Hay , Begbie Stephen , Clingan Philip , Loi Sherene , Sabanathan Dhanusha , Andrea Gombos , Donatienne Taylor , Carlos Barrios , Leandro Brust , Costa Fabiano , de Freitas Junior Ruffo , Roberto Hegg , Lacerda Domicio Carvalho , Lissa Fernando Cezar Toniazzi , Rocha Roberto Odebrecht , Scalabrini Neto Antonio Orlando , Silva Felipe , Cescon David , Danielle Charpentier , Cristiano Ferrario , Xinni Song , Yu Joanne , Alejandro Acevedo , Gallardo Carlos , Salas Claudio , Sanchez Cesar , Eduardo Yañez , Gomez Diaz Alvaro , Sanchez Jesus , Holeckova Petra , Kral Zdenek , Bohuslav Melichar , Katarína Petráková , Prausova Jana , Vesna Glavicic , Jakobsen Erik , Jensen Jeanette , Søren Linnet , Tamás Lörincz , Bonnefoi Herve , Isabelle Desmoulins , Anthony Gonçalvès , Hardy-Bessard Anne-Claire , Luís Teixeira , Blohmer Jens-Uwe , Fasching Peter , Dirk Forstmeyer , Nadia Harbeck , Huober Jens , Kaczerowsky Flores de Sousa Anna , Kurbacher Christian , Sibylle Loibl , Lueftner Diana , Park-Simon Tjoung-Won , Schumann Raquel Von , Pauline Wimberger , Chow Louis , Kwong Ava , Ngan Kai Cheong Roger , Peter Arkosy , Tibor Csőszi , Zsuzsanna Kahán , Landherr László , Mahr Karoly , Gábor Rubovszky , John Crown , Kelly Catherine , O'Reilly Seamus , Saverio Cinieri , DAlessio Antonietta , Ricevuto Enrico , Tomoyuki Aruga , Takaaki Fujii , Inoue Kenichi
2020 The Lancet 1,658 citations

Keywords

MedicineCarboplatinGemcitabineInternal medicinePembrolizumabTriple-negative breast cancerBreast cancerOncologyChemotherapyDocetaxelMetastatic breast cancerPlaceboTaxaneCancerPathologyCisplatinImmunotherapy

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
396
Issue
10265
Pages
1817-1828
Citations
1658
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1658
OpenAlex

Cite This

Javier Cortés, David W. Cescon, Hope S. Rugo et al. (2020). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. The Lancet , 396 (10265) , 1817-1828. https://doi.org/10.1016/s0140-6736(20)32531-9

Identifiers

DOI
10.1016/s0140-6736(20)32531-9